Liquid Biospy Market Forecast 2025 With Players Trovagene, Bio-Rad Laboratories, Fraunhofer-Gesellschaft, Roche, Guardant Health, GRAIL, Inc., QIAGEN, Myriad Genetics, Adaptive Biotechnologies Corp., NeoGenomics Laboratories

The report also includes key market players ' movements, including acquisitions and mergers, the launch of new products, agreements, partnerships, collaborations and joint ventures, research and development, and the regional expansion of key market participants globally and regionally. The CAGR value fluctuation for the Liquid Biospy market during 2018-2025 has been provided in this report. In addition this report has incorporated all drivers and restrictions for the Liquid Biospy market using SWOT analysis.

Global Liquid Biospy Market is expected to reach USD 3848.26 million by 2025, from USD 715.72 million in 2017 growing at a CAGR of 23.4% during the forecast period of 2018 to 2025. Global liquid biopsy market is highly fragmented and is based on new product launches and clinical results of products.

Get Sample Analysis of This Market Information: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-liquid-biopsy-market

The liquid biopsy is a non invasive technique which is used to test blood in order to detect circulating tumor cells. Liquid biopsy is a minimally or non-invasive technology for recognition of molecular biomarkers without the need for costly or invasive actions. It is a simple and non-invasive substitute to surgical biopsies which allows medical doctors to discover a range of information about a disease or a tumour through a simple blood sample. Some of the major players operating in global liquid biopsy market are

· Biocept, Inc.

· Qiagen N.V.

· Roche Diagnostics

· Bio-Rad Laboratories, Inc.

· Myriad Genetics, Inc

· Menarini-Silicon Biosystems.

· Trovagene, Inc.

· Guardant Health, Inc.

· MDX health SA

· Genomic Health, Inc.

· BGI (BGI Diagnostics)

· Caredx, Inc.

· Cynvenio Biosystems, Inc

· Eurofins Scientific Se (Lifecodexx)

Others: Exact Sciences Corporation, Exosome Diagnostics, Inc, Immucor, Laboratory Corporation of America Holdings, Natera, Inc., Raindance Technologies, Inc,, Thermo Fisher Scientific Inc. and Illumina, Inc. among others. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of liquid biopsy market for global, Europe, North America, Asia Pacific and South America.

Different liquid biopsy tests analyse different kinds of tumour material, such as DNA, RNA, proteins, tiny vesicles called exosomes, and whole cells. Liquid biopsy has many applications in the diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, etc. is increasing. For instance, according to a study published in Oncology Journal, In January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC.


Get TOC of Full Report: https://databridgemarketresearch.com/toc/?dbmr=global-liquid-biopsy-market


Major Market Drivers and Restraints:

· Increasing prevalence of cancer

· Increasing preference for non-invasive procedures

· Initiatives undertaken by government and global health organizations

· Technological advancement to augment market revenues

· Rising emphasis on personalized medicine

· Availability of funding for liquid biopsy R&D

· Low sensitivity and specificity


Market Segmentation: Global Liquid Biopsy Market

· The global liquid biopsy market is segmented based on product and service, circulating biomarker, clinical application, end user and geographical segments.

· Based on product and service the market is segmented into

• Assay kits
• Instruments and services

· On the basis of circulating biomarker the market is classified into

• Circulating tumor cells
• Circulating tumor dna (ctdna)
• Cell-free dna
• Extracellular vesicles (evs) and other circulating biomarkers

· On the basis of clinical application the market is segmented into

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring

· Based on application the market is segmented into cancer applications and non-cancer applications. The cancer applications are further sub segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer and other cancers

· Based on geography, the global liquid biopsy market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa.

· Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.


Major Points in the Report

1. To get a comprehensive overview of the Liquid Biospy market.

2. To gain information about the top players in this industry, their product portfolios, and their key strategies.

3. To gain insights about the major regional insights in which the Liquid Biospy is flourishing.

4. Recent industry trends and developments

5. Potential and niche segments/regions exhibiting promising growth

Want Full Report? Enquire Here: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-liquid-biopsy-market

About Us

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get 10% Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research
Toll Free: +1-888-387-2818
Mail: sopan.gedam@databridgemarketresearch.com
http://databridgemarketresearch.com

This release was published on openPR.